New Insulin Combination for Dogs with Well-Regulated Diabetes
Well regulated diabetics dogs on NPH insulin and W/D are being recruited for: An investigation of the action of combined subcutaneous NPH and lispro insulin in dogs
Introduction, Background and Preliminary Data
The two most important components of therapy for diabetes mellitus (DM) in dogs are administration of insulin and dietary management. The goal of insulin treatment is to mimic the biphasic mode of physiologic insulin secretion.
Figure 1. Physiologic insulin secretion in humans
The first phase of insulin secretion consists of a large and rapid increase and decrease in insulin secretion, and the second phase maintains a smaller magnitude plateau.
Basal-bolus therapy is an effective form of combination insulin therapy which mimics biphasic physiologic insulin secretion. The basal-bolus therapy is commonly used for treatment of humans with diabetes mellitus. Boluses of rapidly and short acting insulins (such as lispro insulin) in the example below are given at the time of meals in addition to a longer acting insulin, such as NPH, which provides basal therapy. The goal of the bolus component of therapy is to mimic phase one of insulin secretion and to address postprandial hyperglycemia.
A recent study, by the PennVets diabetes group found that some well-regulated diabetic dogs treated with NPH insulin and W/D develop postprandial hyperglycemia, as in the example below.
Figure 3: postprandial hyperglycemia in a well-regulated diabetic dog treated with NPH human analogue insulin and W/D
The goal of this study is to determine whether basal-bolus lispro and human analogue NPH insulin therapy, given twice daily with meals, would decreases postprandial hyperglycemia and improves clinical signs and glycemic control.
Study expenses, including the price of the lispro insulin, will be covered by the researchers. The study would involve two blood glucose curves performed at a 2 week interval.
Please contact Dr. Rebecka Hess at firstname.lastname@example.org pr 215-898-9427, for further information.
View Study Overview: Previous Page